Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04955990 · ClinicalTrials.gov registry record · Phase 4
A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants
A Phase 4 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 4
- Development phase
- 232
- Enrollment target
NCT04955990 is a Phase 4 study that was terminated before completion, run by Actelion. The registered enrollment target is 232 participants.
The verdict
NCT04955990, a Phase 4 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 232 participants
- Enrollment target
Study Summary
This study is designed to describe pulmonary arterial hypertension (PAH) participants in terms of their clinical characteristics, therapies used, disease progression, and outcomes (example, death, hospitalization, risk category for predicted mortality risk, and patient-reported outcomes \[PROs\]) in real-world clinical practice. This study will collect high-quality real-world data that may be used as a stand-alone dataset or in combination with other studies to address relevant research questions (example, serve as an external control dataset to another study) to support development and access to PAH therapies, as well as to contribute to the knowledge base of PAH through publications.
Interventions
- OTHER PAH Therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2022-12-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04955990
The ClinicalTrials.gov registry entry for NCT04955990 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PAH Therapies is the first listed.
NCT04955990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04955990 about?
NCT04955990 is a clinical study titled "A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants". This study is designed to describe pulmonary arterial hypertension (PAH) participants in terms of their clinical characteristics, therapies used, disease progression, and outcomes (example, death, hospitalization, risk category for predicted mortality risk, and patient-reported outcomes \[PROs\]) in...
What is the current status of trial NCT04955990?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 232 participants. The study started on 2021-10-14. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT04955990?
The interventions under investigation include: PAH Therapies (OTHER).
Who is sponsoring clinical trial NCT04955990?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.